Hemostasis News and Research RSS Feed - Hemostasis News and Research

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.
Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Instrumentation Laboratory today announced the commercialization of their HemosIL Rivaroxaban Testing Solution in Europe. The HemosIL Liquid Anti-Xa assay, when used in conjunction with HemosIL Rivaroxaban Calibrators and HemosIL Rivaroxaban controls offers an automated solution for measurement of rivaroxaban. [More]
Mitek Sports Medicine introduces two new arthroscopic surgery radiofrequency devices

Mitek Sports Medicine introduces two new arthroscopic surgery radiofrequency devices

Mitek Sports Medicine, part of DePuy Synthes Companies of Johnson & Johnson, is introducing two new arthroscopic surgery radiofrequency devices this week at the American Orthopaedic Society for Sports Medicine 2015 Annual Meeting. [More]
OBP Medical introduces CLEAR-TRAC family of disposable surgical retractors

OBP Medical introduces CLEAR-TRAC family of disposable surgical retractors

OBP Medical, the leading global developer of single-use, self-contained, illuminating medical devices, today announced the launch of its CLEAR-TRAC family of disposable surgical retractors. The line—which includes CLEAR-TRAC SP (surgical pocket), CLEAR-TRAC V (vaginal) and new CLEAR-TRAC B (breast)—is the first on the market to offer a built-in, single-use light source. [More]
Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen. [More]
Findings could help improve patient care, reduce cancer screening costs around the world

Findings could help improve patient care, reduce cancer screening costs around the world

A large clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa has found that contrary to expectations, a CT scan of the abdomen and pelvis does not improve cancer detection in people with unexplained blood clots in their legs and lungs. [More]

New winged female Luer lock to barb connectors from Qosina

Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery. [More]
First patient enrolled in CryoLife's PerClot IDE clinical trial

First patient enrolled in CryoLife's PerClot IDE clinical trial

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the enrollment of the first patient in its PerClot Investigational Device Exemption (IDE) clinical trial, the Company's pivotal clinical trial to gain approval to commercialize PerClot in the U.S. [More]
Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics Corporation today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
New ASH report outlines several models for 'systems-based clinical hematologist'

New ASH report outlines several models for 'systems-based clinical hematologist'

A report released today from the American Society of Hematology in its journal, Blood, presents an innovative, sustainable new role for hematologists, particularly those specializing in non-malignant blood diseases, for today’s rapidly changing U.S. health-care system. [More]
Grifols, Alkahest sign definitive agreements

Grifols, Alkahest sign definitive agreements

Grifols, a global healthcare company and leading producer of plasma therapies, and Alkahest, a Redwood City, California based, privately held biopharmaceutical company founded upon the pioneering work of Dr. Tony Wyss-Coray and other leading scientists at Stanford University, today announced that they have signed definitive agreements whereby Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS), including Alzheimer's. [More]
Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers at the UNC School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases. [More]
CryoLife's revenues increase 5% to $37.2M in fourth quarter 2014

CryoLife's revenues increase 5% to $37.2M in fourth quarter 2014

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2014. [More]
Balanced blood product ratios can improve outcomes in severe trauma patients

Balanced blood product ratios can improve outcomes in severe trauma patients

Among patients with severe trauma and major bleeding, those who received a transfusion of a balanced ratio of plasma, platelets, and red blood cells (RBCs) were more likely to have their bleeding stopped and less likely to die due to loss of blood by 24 hours compared to patients who received a transfusion with a higher ratio of RBCs, according to a study in the February 3 issue of JAMA. [More]
Ethicon launches new ECHELON FLEX Powered Vascular Stapler for lung cancer treatment

Ethicon launches new ECHELON FLEX Powered Vascular Stapler for lung cancer treatment

Ethicon has developed a new powered vascular stapler designed to provide greater precision and stability than currently available staplers for critical vessel transections. The new ECHELON FLEX Powered Vascular Stapler has the narrowest anvil of any stapler on the market, an articulating shaft and advanced placement tip that may allow for better visibility, navigation and precise placement during thoracic and other procedures, including VATS lobectomy (Video-Assisted Thoracoscopic Surgery) for lung cancer. [More]
Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). [More]
Universal Biosensors announces release of Siemens Xprecia Stride Coagulation Analyzer

Universal Biosensors announces release of Siemens Xprecia Stride Coagulation Analyzer

Universal Biosensors, Inc. is pleased to announce that Siemens Healthcare Diagnostics Inc. has initiated the European limited release of the Xprecia Stride Coagulation Analyzer, its first point-of-care coagulation testing product. [More]
Elsevier honored at BMA Medical Book Awards ceremony

Elsevier honored at BMA Medical Book Awards ceremony

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that 28 of its professional and scholarly products were honored at the British Medical Association's annual BMA Medical Book Awards ceremony at BMA House in London on Sept. 22, 2014. [More]

Instrumentation Laboratory announces launch of HemosIL Direct Thrombin Inhibitor Assay in Europe

Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC). [More]
Advertisement
Advertisement